 |
blinatumomab |
|---|---|
| Trade Name | Blincyto |
| Orphan Indication | Acute lymphoblastic leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2008-05-16 00:00:00 |
| Sponsor | Amgen, Inc.;One Amgen Center Dr., Mail Stop 17-2-A;Thousand Oaks, California, 91320 |
Related Access Program
Novartis Pharmaceuticals – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute Lymphoblastic Leukemia
ERYtech Pharma – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute lymphoblastic leukemia
ERYtech Pharma – Acute lymphoblastic leukemia
Amgen – Acute lymphoblastic leukemia